Henry Ford Medical Center
Henry Ford Medical Center
Detroit, Michigan, United States7 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | Plaque Psoriasis | Active, not recruiting | Phase 3 | 2026-09-28 | NCT06143878 | |
| Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - A Randomized Clinical Trial in Acute Kidney Injury | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Inflammation, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, acute kidney injury, kidney cortex necrosis, kidney disorder, kidney failure, urinary system disorder | Recruiting | Not applicable | 2026-09-10 | NCT05758077 | |
| Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia | autoimmune hemolytic anemia, warm type | Active, not recruiting | Phase 2 / Phase 3 | 2026-08-31 | NCT04119050 | |
| Prospective Global Registry for the Study of Chronic Total Occlusion Intervention | Arterial Occlusive Diseases, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, heart disorder, myocardial ischemia, vascular disorder | Recruiting | Not stated | 2026-08-19 | NCT02061436 | |
| Optimizing Phototesting and Investigating Photobiology of Visible Light | Healthy | Active, not recruiting | Not applicable | 2026-05-01 | NCT05964907 | |
| Fractionated 1927-nm Non Ablative Thulium Laser in Treating Post Inflammatory Hyperpigmentation | Healthy | Recruiting | Not applicable | 2025-06-25 | NCT06149780 | |
| Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 3 | 2025-05-09 | NCT03562637 |